Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable
esophageal cancer (EC). However, as high as more than 40% of EC patients experienced
locoregional recurrence after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1
checkpoints has demonstrated promising activity in advanced EC. The aim of this study was to
evaluate the efficacy and safety of the combination of toripalimab (an anti-PD-1 antibody)
combined with definitive CRT in locally advanced esophageal squamous cell carcinoma (ESCC).